Edwards Lifesciences (NYSE:EW) had its target price upped by Morgan Stanley from $180.00 to $197.00 in a research note released on Monday. Morgan Stanley currently has an overweight rating on the medical research company’s stock.

Several other brokerages also recently weighed in on EW. Canaccord Genuity reiterated a buy rating and issued a $215.00 target price (up from $190.00) on shares of Edwards Lifesciences in a research note on Monday. Bank of America lifted their target price on Edwards Lifesciences from $190.00 to $215.00 and gave the company a buy rating in a research note on Monday. Wells Fargo & Co lifted their target price on Edwards Lifesciences from $188.00 to $202.00 and gave the company an outperform rating in a research note on Monday. UBS Group lifted their target price on Edwards Lifesciences from $175.00 to $180.00 and gave the company a neutral rating in a research note on Tuesday, March 12th. Finally, Citigroup lifted their target price on Edwards Lifesciences from $119.00 to $130.00 and gave the company a sell rating in a research note on Monday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $176.00.

NYSE:EW opened at $188.91 on Monday. The company has a market cap of $39.34 billion, a P/E ratio of 40.29, a PEG ratio of 2.44 and a beta of 0.90. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. Edwards Lifesciences has a 52-week low of $123.00 and a 52-week high of $197.86.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share for the quarter, meeting the consensus estimate of $1.17. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. The company had revenue of $977.70 million for the quarter, compared to the consensus estimate of $973.72 million. During the same period last year, the business posted $0.94 EPS. On average, research analysts expect that Edwards Lifesciences will post 5.21 EPS for the current fiscal year.

In related news, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction on Thursday, January 3rd. The stock was sold at an average price of $143.90, for a total transaction of $4,719,920.00. Following the completion of the transaction, the chief executive officer now directly owns 75,926 shares of the company’s stock, valued at $10,925,751.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Huimin Wang sold 4,000 shares of Edwards Lifesciences stock in a transaction on Friday, January 4th. The stock was sold at an average price of $145.33, for a total value of $581,320.00. Following the transaction, the vice president now directly owns 35,224 shares of the company’s stock, valued at $5,119,103.92. The disclosure for this sale can be found here. Insiders sold a total of 169,668 shares of company stock valued at $27,195,828 over the last three months. Insiders own 1.84% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Executive Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $25,000. Sontag Advisory LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Lindbrook Capital LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $27,000. Capital Financial Planning LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $28,000. Finally, Nelson Roberts Investment Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $30,000. 83.09% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: What factors cause inflation to rise?

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.